|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Neurology (M.S., H.-C.D.), University of Duisburg-Essen, Germany; Divisions of Preventive Medicine and Aging (T.K.), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and Department of Epidemiology, Harvard School of Public Health, Boston, MA; and Institute of Pharmacology (I.G., G.T., D.R.), Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, University Hospital, Ernst-Moritz Arndt University, Greifswald, Germany.
Address correspondence and reprint requests to Dr. Markus Schürks, Department of Neurology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; e-mail: schuerks{at}hotmail.com.
The G1246A polymorphism in the gene of the hypocretin receptor 2 (HCRTR2) has been linked to the risk for cluster headache (CH). The authors examined this association in a large sample of 226 patients with CH and 266 controls from Germany. The genotype and allele distribution varied significantly between patients and controls. Homozygous carriers of the G-allele had a twofold increase in risk for CH (OR 1.97; 95% CI 1.32 to 2.92; p = 0.0007).
This article was previously published in electronic format as an Expedited E-Pub on March 22, 2006, at www.neurology.org.
Supported by "Cluster-Kopfschmerz Selbsthilfe Gruppen Deutschland" (CSG).
Disclosure: The authors report no conflicts of interest.
Received August 1, 2005. Accepted in final form January 18, 2006.
See also page 1888
Related articles in Neurology:
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |